Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brendan L Hagerty

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
World Journal of Oncology|October 23, 2023
Biology of Mesothelin and Clinical Implications: A Review of Existing LiteratureBrendan L Hagerty, Kazuaki Takabe
Diseases of the Colon and Rectum|March 29, 2023
ReplyBrendan L Hagerty, Andrew M Blakely
American Journal of Cancer Research|October 11, 2023
High Mesothelin expression in pancreatic adenocarcinoma is associated with aggressive tumor features but not prognosisBrendan L Hagerty, Masanori Oshi, Itaru Endo, et al.
Annals of Surgical Oncology|April 21, 2025
ASO Visual Abstract: Mesothelin (MSLN) is Highly Expressed in Triple-Negative Breast Cancer and is Associated with Enhanced Cell Proliferation and Pro-inflammatory Tumor MicroenvironmentBrendan L Hagerty, Takumi Sato, Rongrong Wu, et al.
Annals of Surgical Oncology|March 13, 2025
Mesothelin (MSLN) is Highly Expressed in Triple Negative Breast Cancer and is Associated with Enhanced Cell Proliferation and Proinflammatory Tumor MicroenvironmentBrendan L Hagerty, Takumi Sato, Rongrong Wu, et al.
Annals of Surgical Oncology|April 24, 2025
ASO Author Reflections: Is Mesothelin a Promising Option for Molecular Targeted Therapies in Triple Negative Breast Cancer?Takumi Sato, Brendan L Hagerty, Rongrong Wu, et al.
Biomolecules|July 2, 2020
Mesothelin-Targeted Recombinant Immunotoxins for Solid TumorsBrendan L Hagerty, Guillaume J Pegna, Jian Xu, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 4, 2024
Contemporary outcomes for resected type 1-3 gastroesophageal junction adenocarcinoma: a single-center experienceZachary E Stiles, Brendan L Hagerty, Maureen Brady, et al.
Journal of Surgical Oncology|August 19, 2024
Chemotherapy switch for nonresponse or progression on neoadjuvant chemotherapy for pancreatic adenocarcinomaBrendan L Hagerty, Fatemeh Fekrmandi, Tyce Schneider, et al.
JAMA Oncology|May 22, 2020
Trends of Clinician Adherence to Evidence-Based Recommendations for Multidisciplinary Oncology Care for Patients With Esophageal CancerJohn G Aversa, Laurence P Diggs, Brendan L Hagerty, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
World Journal of Oncology|October 23, 2023
Biology of Mesothelin and Clinical Implications: A Review of Existing LiteratureBrendan L Hagerty, Kazuaki Takabe
Diseases of the Colon and Rectum|March 29, 2023
ReplyBrendan L Hagerty, Andrew M Blakely
American Journal of Cancer Research|October 11, 2023
High Mesothelin expression in pancreatic adenocarcinoma is associated with aggressive tumor features but not prognosisBrendan L Hagerty, Masanori Oshi, Itaru Endo, et al.
Annals of Surgical Oncology|April 21, 2025
ASO Visual Abstract: Mesothelin (MSLN) is Highly Expressed in Triple-Negative Breast Cancer and is Associated with Enhanced Cell Proliferation and Pro-inflammatory Tumor MicroenvironmentBrendan L Hagerty, Takumi Sato, Rongrong Wu, et al.
Annals of Surgical Oncology|March 13, 2025
Mesothelin (MSLN) is Highly Expressed in Triple Negative Breast Cancer and is Associated with Enhanced Cell Proliferation and Proinflammatory Tumor MicroenvironmentBrendan L Hagerty, Takumi Sato, Rongrong Wu, et al.
Annals of Surgical Oncology|April 24, 2025
ASO Author Reflections: Is Mesothelin a Promising Option for Molecular Targeted Therapies in Triple Negative Breast Cancer?Takumi Sato, Brendan L Hagerty, Rongrong Wu, et al.
Biomolecules|July 2, 2020
Mesothelin-Targeted Recombinant Immunotoxins for Solid TumorsBrendan L Hagerty, Guillaume J Pegna, Jian Xu, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|May 4, 2024
Contemporary outcomes for resected type 1-3 gastroesophageal junction adenocarcinoma: a single-center experienceZachary E Stiles, Brendan L Hagerty, Maureen Brady, et al.
Journal of Surgical Oncology|August 19, 2024
Chemotherapy switch for nonresponse or progression on neoadjuvant chemotherapy for pancreatic adenocarcinomaBrendan L Hagerty, Fatemeh Fekrmandi, Tyce Schneider, et al.
JAMA Oncology|May 22, 2020
Trends of Clinician Adherence to Evidence-Based Recommendations for Multidisciplinary Oncology Care for Patients With Esophageal CancerJohn G Aversa, Laurence P Diggs, Brendan L Hagerty, et al.
Pageof 2